现代医药卫生
現代醫藥衛生
현대의약위생
MODERN MEDICINE HEALTH
2014年
11期
1615-1617
,共3页
林芳%杨明金%唐万艳%蒋幼凡
林芳%楊明金%唐萬豔%蔣幼凡
림방%양명금%당만염%장유범
癌,非小细胞肺%基因,erbB-1%受体,表皮生长因子%基因%突变
癌,非小細胞肺%基因,erbB-1%受體,錶皮生長因子%基因%突變
암,비소세포폐%기인,erbB-1%수체,표피생장인자%기인%돌변
Carcinoma,non-small-cell lung%Genes,erbB-1%Receptor,epidermal growth factor%Genes%Mutation
目的:探讨非小细胞肺癌表皮生长因子受体(EGFR)第19、21号外显子突变与其临床病理特征、家族史的关系,以及对突变阳性患者使用表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)靶向治疗的效果。方法采用扩增阻滞突变系统聚合酶链反应技术对EGFR第19、21号外显子进行检测。结果162例非小细胞肺癌患者发生EGFR突变阳性63例,突变阳性率为38.89%。腺癌、女性、非吸烟者、有肺癌及其他恶性肿瘤家族史的非小细胞肺癌患者EGFR突变率明显升高,差异有统计学意义(P<0.05),但与患者年龄,肿瘤分级、分期、大小、是否转移无关(P>0.05)。非小细胞肺癌发生EGFR突变阳性使用EGFR-TKIs靶向治疗患者的中位生存期明显长于未治疗及其他药物化疗患者,差异有统计学意义(P<0.01)。结论非小细胞肺癌患者EGFR突变筛查应作为常规临床检测指标,特别是对于有肿瘤家族史患者更具有临床意义。
目的:探討非小細胞肺癌錶皮生長因子受體(EGFR)第19、21號外顯子突變與其臨床病理特徵、傢族史的關繫,以及對突變暘性患者使用錶皮生長因子受體酪氨痠激酶抑製劑(EGFR-TKIs)靶嚮治療的效果。方法採用擴增阻滯突變繫統聚閤酶鏈反應技術對EGFR第19、21號外顯子進行檢測。結果162例非小細胞肺癌患者髮生EGFR突變暘性63例,突變暘性率為38.89%。腺癌、女性、非吸煙者、有肺癌及其他噁性腫瘤傢族史的非小細胞肺癌患者EGFR突變率明顯升高,差異有統計學意義(P<0.05),但與患者年齡,腫瘤分級、分期、大小、是否轉移無關(P>0.05)。非小細胞肺癌髮生EGFR突變暘性使用EGFR-TKIs靶嚮治療患者的中位生存期明顯長于未治療及其他藥物化療患者,差異有統計學意義(P<0.01)。結論非小細胞肺癌患者EGFR突變篩查應作為常規臨床檢測指標,特彆是對于有腫瘤傢族史患者更具有臨床意義。
목적:탐토비소세포폐암표피생장인자수체(EGFR)제19、21호외현자돌변여기림상병리특정、가족사적관계,이급대돌변양성환자사용표피생장인자수체락안산격매억제제(EGFR-TKIs)파향치료적효과。방법채용확증조체돌변계통취합매련반응기술대EGFR제19、21호외현자진행검측。결과162례비소세포폐암환자발생EGFR돌변양성63례,돌변양성솔위38.89%。선암、녀성、비흡연자、유폐암급기타악성종류가족사적비소세포폐암환자EGFR돌변솔명현승고,차이유통계학의의(P<0.05),단여환자년령,종류분급、분기、대소、시부전이무관(P>0.05)。비소세포폐암발생EGFR돌변양성사용EGFR-TKIs파향치료환자적중위생존기명현장우미치료급기타약물화료환자,차이유통계학의의(P<0.01)。결론비소세포폐암환자EGFR돌변사사응작위상규림상검측지표,특별시대우유종류가족사환자경구유림상의의。
Objective To investigate the associations between the mutations of exons 19 and 21 of epidermal growth fac-tor receptor(EGFR) genes and clinicopathological characteristics,and family history in non-small cell lung cancer(NSCLC),and further explore the curative effect of targeted therapy in patients with positive mutations by epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs). Methods Amplification Refractory Mutation System-Polymerase Chain Reaction(ARMS-PCR) was applied to detect the mutations of exons 19 and 21 of EGFR. Results The results showed that 63 patients were with EGFR muta-tions in 162 NSCLC patients,and the positive rate of mulation was 38.89%. Furthermore,the mutation rate was obviously higher in NSCLC patients with adenocarcinoma,woman,non-smoking,lung cancer or family history of malignancy,and the difference had statistical significance(P<0.05). However,the mutation rate had no significant correlation with patients′age,tumor grade,stage, size,metastasis or not(P>0.05). The median survival time of the NSCLC patients,who were treated with EGFR-TKIs,was prolonged significantly in patients with positive mutationwith statistically significant difference (P<0.01). Conclusion The screening of EGFR mutations should be used as a routine examination in the patients with NSCLC ,especially it has more clinical significance in patients with family history of malignant tumor.